Search results
EAN 2024: safinamide surpasses rasagiline as add-on PD therapy
Pharmaceutical Technology· 9 hours agoSafinamide has a higher patient response rate against placebo than rasagiline, but did not appear to...
More endpoints met in Insmed’s Phase III brensocatib trial
Clinical Trials Arena· 1 day agoThe forced expiratory volume (FEV1) data from the study (NCT04594369) shows a statistically...
Roche’s Phase II/III NSCLC treatment trial fails to meet primary endpoints
Clinical Trials Arena· 16 hours agoThe international, placebo-controlled, randomised, double-blinded trial enrolled 542 priorly...
Cartesian reports positive results from Phase IIb myasthenia gravis trial
Clinical Trials Arena· 2 days agoIIb clinical trial evaluating Descartes-08, an autologous, mRNA-engineered chimeric antigen receptor...
FDA approves Eli Lilly’s Kisunla (donanemab) for early AD
Pharmaceutical Technology· 15 hours agoThe approval of Kisunla was based on data from the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511)....
EAN 2024: encouraging analyses of pridopidine Healey ALS platform trial
Clinical Trials Arena· 3 days agoShared infrastructure and common protocol allow sharing of placebo data The Healey ALS platform...
J&J looks to challenge argenx’s Vyvgart with positive Phase III data
Pharmaceutical Technology· 3 days agoGlobalData is the parent company of Pharmaceutical Technology. Positive Phase III results The ...
Boehringer Ingelheim and Gubra begin Phase I trial of drug candidate for obesity
Clinical Trials Arena· 3 days agoBoehringer Ingelheim and Gubra have initiated a Phase I clinical trial of BI 3034701, a long-acting...
Blockbuster diabetes & obesity drug gets nod for India launch but may be available only next year
Theprint· 2 days ago“After detailed deliberation, the committee recommended for grant of permission for import and marketing of tirzepatide 2.5mg/0.5ml, 5mg/0.5ml, 7.5mg/0.5ml, 10mg/0.5ml, 12.5mg/0.5ml and 15mg ...
IntelGenx reports preliminary data from Phase IIa Alzheimer’s disease trial
Clinical Trials Arena· 14 hours agoWhile the final study report is expected in the third quarter of 2024, the topline analysis revealed...